ABSTRACT
OBJECTIVE: The aim: To analyze the dynamics of daily monitoring of blood pressure, intracardiac (according to echocardiography), peripheral hemodynamics (according to ultrasound of the vessels of the lower extremity), the thickness of the intima-media complex (according to carotid sonography) in patients with hypertension the effect of treatment with a combination of lisinopril and amlodipine. PATIENTS AND METHODS: Materials and methods: The study included 40 patients with hypertension with 2 (29 patients) and 3 (11 patients) degrees of hypertension in combination with AOLE with I-III stages of chronic insufficiency of the lower extremity, which revealed hyperkinetic, eukinetic, and hypokinetic types of hypertension with a predominance of the sympathetic nervous system. The groups are comparable in age, sex, duration of hypertension, and medications received in the previous stages. For antihypertensive therapy, the most common drugs for use were selected - lisinopril + amplodipine in fixed doses of 10 and 5 mg, respectively. If after 2 weeks we did not reduce the mean level of SBP and DBP by 10% or more from baseline, we doubled the dose of lisinopril without changing the dose of amlodipine. RESULTS: Results: After 6 months of treatment, in particular, an increase in the pulse index - by 24.8%, a decrease in the resistance index - by 21.1%, an increase in linear and volumetric blood velocity - by 25.6% and 27.4%, respectively, while achieving the target blood pressure. CONCLUSION: Conclusions: It is proved that in the absence of individual contraindications the combination of lisinopril and amlodipine is optimal and universal for effective treatment of patients with hypertension in combination with AOLE in all types of central hemodynamics.
Subject(s)
Arteriosclerosis Obliterans , General Practice , Hypertension , Humans , Amlodipine/therapeutic use , Amlodipine/pharmacology , Lisinopril/therapeutic use , Lisinopril/pharmacology , Antihypertensive Agents/therapeutic use , Antihypertensive Agents/pharmacology , Arteriosclerosis Obliterans/chemically induced , Arteriosclerosis Obliterans/drug therapy , Hypertension/complications , Hypertension/drug therapy , Blood Pressure , ComorbidityABSTRACT
The aim in this study was to investigate the efficacy and safety of domestic paclitaxel-coated balloon (DCB) and bare metal stent (BMS) in the treatment of Transatlantic Cooperative Organization Consensus II (ASC II) types A-C femoral-popliteal arteriosclerosis obliterans (ASO). A total of 103 patients with ASC II A-C femoropopliteal ASO, who received treatment in our hospital from March 2020 to March 2021, were retrospectively selected and divided into the DCB group (n = 56) and BMS group (n = 47), according to treatment methods. The general clinical data and surgical results were compared between the two groups. The patients were followed up, and the primary patency rate, restenosis rate, freedom from target lesion revascularization (f-TLR), and limb preservation rate were recorded. The liver and kidney functions before and after operation and the occurrence of major postoperative adverse events were recorded. The operation was successful in both groups. The minimum diameter of the DCB group was smaller than that of the BMS group after treatment (P < 0.05). At 6 and 12 months after operation, the Rutherford classification decreased and ABI index increased in both groups (P < 0.05), but there was no significant difference (P > 0.05). At 6 and 12 months after surgery, f-TLR was significantly higher in the DCB group than in the BMS group (P < 0.05); at 12 months after surgery, the restenosis rate was lower in the DCB group than in the BMS group (P < 0.05). There was no significant difference in the primary patency rate and limb preservation rate at 6 and 12 months after operation between the two groups (P > 0.05). Before and after operation, there was no significant difference in liver and kidney function between the two groups (P > 0.05). Within 12 months after surgery, 1 patient in the DCB group developed puncture site hematoma 3 days after surgery, and 1 patient in the BMS group developed acute thrombosis 1 day after surgery, and no intervention-related deaths occurred. Domestic paclitaxel DCB can achieve better f-TLR and lower restenosis rate than BMS in the treatment of type II A-C femoral-popliteal artery ASO. Short-term and medium-term efficacy and safety are comparable to BMS.
Subject(s)
Arteriosclerosis Obliterans , Peripheral Arterial Disease , Arteriosclerosis Obliterans/chemically induced , Arteriosclerosis Obliterans/drug therapy , Coated Materials, Biocompatible , Constriction, Pathologic/chemically induced , Constriction, Pathologic/drug therapy , Humans , Paclitaxel/adverse effects , Peripheral Arterial Disease/drug therapy , Peripheral Arterial Disease/surgery , Popliteal Artery/surgery , Retrospective Studies , Stents , Treatment OutcomeABSTRACT
A case of unilateral retinal vascular occlusion secondary to the use of oral contraceptives is presented. The vision was only slightly affected. Fundus examination revealed tortuosity of venules around the macular area and alteration of the pigment epithelium indicating low-grade retinal vein occlusion. Periodic ophthalmologic examination is suggested to women on oral contraceptives to prevent serious thromboembolic complications.
Subject(s)
Arteriosclerosis Obliterans/chemically induced , Contraceptives, Oral/adverse effects , Retinal Vessels , Adult , Arteriosclerosis Obliterans/diagnostic imaging , Female , Fluorescein Angiography , Humans , Radiography , Retinal Vessels/diagnostic imagingABSTRACT
PIP: 2 case reports of ischamic symptoms from aorto-iliac occlusion in premenopausal women (ages 29 and 44 years) which began during medication with oral contraceptives suggest that oral contraceptives may be dangerous to patients with a latent tendency to arterial disease and that such patients can be identified before complications arise.^ieng
